Manfred P. Lutz

Universitätsklinikum des Saarlandes — Germany

Medicine · Health Sciences

41h-index7.7kcitations204works0.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Colorectal Cancer Treatments and Studies(55), Pancreatic and Hepatic Oncology Research(52), Gastric Cancer Management and Outcomes(45), Lung Cancer Treatments and Mutations(28), Cancer Genomics and Diagnostics(27)

Publications204 total

Systemic chemotherapy for patients with resectable or resected colorectal cancer liver metastases: An individual patient data meta-analysis
European Journal of Cancer·2025
Predictive criteria for overall survival and treatment duration of 2nd-line chemotherapy in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216)
British Journal of Cancer·2025Open Access
2251P Immune features of the tumor microenvironment are mirrored in PBMCs and predict second-line outcome in advanced pancreatic cancer: Insights from the PREDICT trial
Annals of Oncology·2025
An immune responsive tumor microenvironment imprints into PBMCs and predicts outcome in advanced pancreatic cancer: lessons from the PREDICT trial
Molecular Cancer·2025· 1 citedOpen Access
Five-year outcomes of perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (the NEONAX trial): A randomized phase II trial of the AIO pancreatic cancer group.
Journal of Clinical Oncology·2025
A PBMC and machine learning based biomarker signature to predict second line chemotherapy success in advanced PDAC: Translational data of the PREDICT trial—A prospective, multicenter, trial of the AIO Pancreatic Cancer Group (AIO-PAK-0216).
Journal of Clinical Oncology·2025
Second-line therapy with Nal-IRI/5-FU/FA after failure of gemcitabine/nab-paclitaxel in advanced pancreatic cancer (PC): Predictive role of 1st-line therapy (PREDICT) and impact of quality of life (QoL).
Journal of Clinical Oncology·2025
Percutaneous endoscopic colostomy to relieve malignant bowel obstruction
European Journal of Case Reports in Internal Medicine·2024· 1 citedOpen Access
Preoperative Chemoradiotherapy vs Chemotherapy for Adenocarcinoma of the Esophagogastric Junction
JAMA Network Open·2024· 9 citedOpen Access
386P Exploratory biomarker analysis based on the PREDICT trial (AIO-PAK-0216) for response prediction to second-line nal-IRI/5-FU/FA chemotherapy (CTX) in metastatic PDAC patients (mPDAC Pts)
Annals of Oncology·2024
Advances in the management of hepatobiliary and pancreatic malignancies: highlights from the ESMO Annual Meeting 2023 by the EORTC GI Tract Cancer Group
ESMO Gastrointestinal Oncology·2024· 1 citedOpen Access
Pankreaskarzinom: Klinik, Labordiagnostik und bildgebende Diagnostik
Springer Reference Medizin·2024
Supplementary Material for: Joint linkage and association analysis using GENEHUNTER-MODSCORE with an application to familial pancreatic cancer
Figshare·2024Open Access
1624P Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Annals of Oncology·2023· 1 citedOpen Access
Implementation of endoscopic submucosal dissection in Europe: survey after 10 ESD Expert Training Workshops, 2009 to 2018
iGIE·2023· 2 citedOpen Access
Prediction of early treatment failure of second-line nal-iri/5-FU/FA in patients with advanced pancreatic adenocarcinoma (AIO-PAK-0216).
Journal of Clinical Oncology·2023
Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial.
Journal of Clinical Oncology·2023
Early Detection of Pancreatic Cancer
Oncology Research and Treatment·2023· 4 citedOpen Access
Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)—a randomized phase II trial of the AIO pancreatic cancer group
Annals of Oncology·2022· 146 citedOpen Access
Perioperative oder adjuvante Systemtherapie mit nab-Paclitaxel plus Gemcitabin bei resektablem Pankreaskarzinom: Weitere Ergebnisse der randomisierten Phase-II-Studie NEONAX Studie der AIO
Zeitschrift für Gastroenterologie·2022Open Access
page 1 of 11Next →

Frequent Co-authors

Eric Van Cutsem(18), Murielle Mauer(13), Bernard Nordlinger(13), Florian Lordick(10), Michel Ducreux(9), Karin Haustermans(8), John Zalcberg(8), Wolf O. Bechstein(7), Markus Moehler(6), Hans‐Joachim Schmoll(6), Daniela E. Aust(6), Theo J. M. Ruers(5), J. Wils(5), Thomas Seufferlein(5), Arnaud Roth(5), Baruch Brenner(5), Ralf‐Dieter Hofheinz(5), Werner Scheithauer(4), Peter Reichardt(4), Graeme J. Poston(4)